FAKTOR-OPTIONSSCHEIN - MODERNA | Market Closed - Boerse Frankfurt Warrants 20:38:08 19/06/2024 BST | ||
| 0.55 EUR | +3.77% |
|
| Current month | +14.58% | ||
| 1 month | -9.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 0.55 | +3.77% |
| 18/06/24 | 0.53 | +6.00% |
| 17/06/24 | 0.5 | +2.04% |
| 14/06/24 | 0.49 | +8.89% |
| 13/06/24 | 0.45 | +2.27% |
Real-time Boerse Frankfurt Warrants
Last update June 19, 2024 at 08:38 pm
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF09EA |
| ISIN | DE000SF09EA9 |
| Date issued | 09/06/2021 |
| Strike | 219.8 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 9.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.81 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.01 € |
| Spread % | 1.79% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- Certificat